2015 News Releases

News Releases | Events
Keyword Search
 
2018 | 2017 | 2016 | 2015 | 2014
Axsome Therapeutics Announces Closing of Initial Public OfferingNovember 24, 2015NEW YORK, Nov. 24, 2015 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical stage biopharmaceutical company developing novel therapies for the management of pain and other central nervous system (CNS) disorders, today announced the closing of its initial public offering of 5,666,667 shares of its common stock at a public offering price of $9.00 per share. Axsome Therapeutics has granted the underwriters a 30-day option to purchase up to an aggregate of 850,000 additional shar... Read MoreAxsome Therapeutics Announces Pricing of Initial Public OfferingNovember 19, 2015NEW YORK, Nov. 19, 2015 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc., a clinical stage biopharmaceutical company developing novel therapies for the management of pain and other central nervous system (CNS) disorders, today announced the pricing of its initial public offering of 5,666,667 shares of its common stock at a public offering price of $9.00 per share. Axsome Therapeutics has granted the underwriters a 30-day option to purchase up to an aggregate of 850,000 additional shares of common... Read MoreAxsome Therapeutics Announces Enrollment of the First Patient in a Phase 3 Trial of AXS-02 for Complex Regional Pain Syndrome (CRPS)August 10, 2015AXS-02 is an oral, non-opioid treatment with a novel mechanism of action for chronic pain CRPS is a debilitating pain syndrome with no approved pharmacological treatmentNEW YORK, Aug. 10, 2015 (GLOBE NEWSWIRE) — Axsome Therapeutics, Inc., a biopharmaceutical company developing novel therapies for the treatment of pain and other central nervous system (CNS) disorders, today announced the enrollment of the first patient in the CREATE-1 (CRPS Treatment Evaluation 1) study—a Phase 3 trial evaluati... Read MoreAxsome Therapeutics Announces Appointment of Randall Kaye, M.D. as Chief Medical OfficerApril 9, 2015NEW YORK, Apr. 09, 2015 (GLOBE NEWSWIRE) — Axsome Therapeutics, Inc., a biopharmaceutical company developing novel therapies for the treatment of pain and other central nervous system (CNS) disorders, today announced the appointment of Randall Kaye, M.D. as Chief Medical Officer (CMO), effective immediately. Dr. Kaye will oversee the development of the Company’s pipeline, including its two late-stage clinical programs, AXS-02 and AXS-05.“We are pleased to have Dr. Kaye as Chief Medical Officer o... Read MoreAxsome Therapeutics Appoints World Leading Experts to Depression Scientific Advisory BoardMarch 19, 2015NEW YORK, March 19, 2015 (GLOBE NEWSWIRE) — Axsome Therapeutics, Inc., a biopharmaceutical company developing novel therapies for the treatment of pain and other central nervous system (CNS) disorders, today announced the formation of its Depression Scientific Advisory Board (“Depression SAB”) comprised of leading experts in the areas of depression, U.S. Food and Drug Administration (FDA) regulations, and clinical trial design. These experts will provide key scientific, clinical, and strategic g... Read MoreAxsome Therapeutics Announces FDA Fast Track Designation for AXS-02 for the Treatment of Pain Associated With Complex Regional Pain SyndromeMarch 5, 2015NEW YORK, March 5, 2015 (GLOBE NEWSWIRE) — Axsome Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation for AXS-02 for the treatment of pain associated with complex regional pain syndrome (CRPS). AXS- 02 is an oral, non-opioid, potentially first-in-class pain therapeutic being developed by Axsome for the treatment of chronic pain caused by CRPS.CRPS is a debilitating condition characterized by severe pain in a limb, accompanied by auto... Read More
Print PageE-mail PageRSS FeedsE-mail AlertsFinancial Tear Sheet